Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions

Frederic Castinetti 1, 2, 3, * Frédéric Albarel 4, 3, 2 Françoise Archambeaud 5 Jérôme Bertherat 6, 7 Benjamin Bouillet 8, 9 Perrine Buffier 8 Claire Briet 10, 11, 12 Bertrand Cariou 13, 14 Ph. Caron 15 Olivier Chabre 16 Philippe Chanson 17, 18 Christine Cortet 19 Christine Do Cao 19 Delphine Drui 14, 13 Magali Haissaguerre 20, 21 Ségolène Hescot 22 Frédéric Illouz 23 Emmanuelle Kuhn 18, 17 Najiba Lahlou Emilie Merlen 19 Véronique Raverot 24 Sarra Smati 13, 14 Bruno Vergès 8, 9 Françoise Borson-Chazot 25, 26
* Auteur correspondant
Abstract : The present final consensus statement of the French Society of Endocrinology lays out the assessments that are to be systematically performed before and during anticancer treatment by immunotherapy, tyrosine kinase inhibitors or mTOR inhibitors, even without onset of any endocrinopathy. It also discusses the CTCAE adverse event grading system in oncology and the difficulty of implementing it for endocrine side-effects of these anticancer treatments. Notably, this is why certain treatment steps applied in other side-effects (e.g., high-dose corticosteroids, contraindications to immunotherapy, etc.) need to be discussed before implementation for endocrine side-effects.
Liste complète des métadonnées

https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01979955
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : lundi 14 janvier 2019 - 09:41:34
Dernière modification le : vendredi 23 octobre 2020 - 14:54:52

Identifiants

Citation

Frederic Castinetti, Frédéric Albarel, Françoise Archambeaud, Jérôme Bertherat, Benjamin Bouillet, et al.. Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions. Annales d'Endocrinologie, Elsevier Masson, 2018, 79 (5), pp.591-595. ⟨10.1016/j.ando.2018.07.005⟩. ⟨hal-01979955⟩

Partager

Métriques

Consultations de la notice

441